These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31735642)

  • 21. A Type IV-A CRISPR-Cas System in
    Crowley VM; Catching A; Taylor HN; Borges AL; Metcalf J; Bondy-Denomy J; Jackson RN
    CRISPR J; 2019 Dec; 2(6):434-440. PubMed ID: 31809194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure of the miniature type V-F CRISPR-Cas effector enzyme.
    Takeda SN; Nakagawa R; Okazaki S; Hirano H; Kobayashi K; Kusakizako T; Nishizawa T; Yamashita K; Nishimasu H; Nureki O
    Mol Cell; 2021 Feb; 81(3):558-570.e3. PubMed ID: 33333018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
    Moreb EA; Hutmacher M; Lynch MD
    CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-Time Observation of Target Search by the CRISPR Surveillance Complex Cascade.
    Xue C; Zhu Y; Zhang X; Shin YK; Sashital DG
    Cell Rep; 2017 Dec; 21(13):3717-3727. PubMed ID: 29281822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of single guide RNA transcription for efficient CRISPR/Cas-based genomic engineering.
    Ui-Tei K; Maruyama S; Nakano Y
    Genome; 2017 Jun; 60(6):537-545. PubMed ID: 28177825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragmentation of the CRISPR-Cas Type I-B signature protein Cas8b.
    Richter H; Rompf J; Wiegel J; Rau K; Randau L
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2993-3000. PubMed ID: 28238733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approaches to study CRISPR RNA biogenesis and the key players involved.
    Behler J; Hess WR
    Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reconstitution and biochemical characterization of ribonucleoprotein complexes in Type I-E CRISPR-Cas systems.
    Xiao Y; Ke A
    Methods Enzymol; 2019; 616():27-41. PubMed ID: 30691647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining the Specificity of Cascade Binding, Interference, and Primed Adaptation
    Cooper LA; Stringer AM; Wade JT
    mBio; 2018 Apr; 9(2):. PubMed ID: 29666291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Essential requirements for the detection and degradation of invaders by the Haloferax volcanii CRISPR/Cas system I-B.
    Maier LK; Lange SJ; Stoll B; Haas KA; Fischer S; Fischer E; Duchardt-Ferner E; Wöhnert J; Backofen R; Marchfelder A
    RNA Biol; 2013 May; 10(5):865-74. PubMed ID: 23594992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding the Biologist's Toolkit with CRISPR-Cas9.
    Sternberg SH; Doudna JA
    Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cas4 Facilitates PAM-Compatible Spacer Selection during CRISPR Adaptation.
    Kieper SN; Almendros C; Behler J; McKenzie RE; Nobrega FL; Haagsma AC; Vink JNA; Hess WR; Brouns SJJ
    Cell Rep; 2018 Mar; 22(13):3377-3384. PubMed ID: 29590607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation CRISPR-Cas for genome editing: focusing on the Cas protein and PAM.
    Tang LC; Gu F
    Yi Chuan; 2020 Mar; 42(3):236-249. PubMed ID: 32217510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three New Cs for CRISPR: Collateral, Communicate, Cooperate.
    Varble A; Marraffini LA
    Trends Genet; 2019 Jun; 35(6):446-456. PubMed ID: 31036344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of nucleotide identity in effective CRISPR target escape mutations.
    Künne T; Zhu Y; da Silva F; Konstantinides N; McKenzie RE; Jackson RN; Brouns SJ
    Nucleic Acids Res; 2018 Nov; 46(19):10395-10404. PubMed ID: 30107450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection.
    East-Seletsky A; O'Connell MR; Knight SC; Burstein D; Cate JH; Tjian R; Doudna JA
    Nature; 2016 Oct; 538(7624):270-273. PubMed ID: 27669025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA and RNA interference mechanisms by CRISPR-Cas surveillance complexes.
    Plagens A; Richter H; Charpentier E; Randau L
    FEMS Microbiol Rev; 2015 May; 39(3):442-63. PubMed ID: 25934119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.